HRP20120944T1 - Kondenzirani spoj indana - Google Patents
Kondenzirani spoj indana Download PDFInfo
- Publication number
- HRP20120944T1 HRP20120944T1 HRP20120944AT HRP20120944T HRP20120944T1 HR P20120944 T1 HRP20120944 T1 HR P20120944T1 HR P20120944A T HRP20120944A T HR P20120944AT HR P20120944 T HRP20120944 T HR P20120944T HR P20120944 T1 HRP20120944 T1 HR P20120944T1
- Authority
- HR
- Croatia
- Prior art keywords
- hexahydro
- indeno
- pyridine
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
- -1 indane compound Chemical class 0.000 title claims 3
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N benzocyclopentane Natural products C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims 18
- 150000001875 compounds Chemical class 0.000 claims 15
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 208000024827 Alzheimer disease Diseases 0.000 claims 4
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 4
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 4
- 208000019695 Migraine disease Diseases 0.000 claims 4
- 208000018737 Parkinson disease Diseases 0.000 claims 4
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 4
- 208000013677 cerebrovascular dementia Diseases 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- KNZJGWSYCJGDEY-UHFFFAOYSA-N 4a-phenyl-1,2,3,4,5,9b-hexahydroindeno[1,2-b]pyridine Chemical compound C1C2=CC=CC=C2C2NCCCC12C1=CC=CC=C1 KNZJGWSYCJGDEY-UHFFFAOYSA-N 0.000 claims 3
- 208000019901 Anxiety disease Diseases 0.000 claims 3
- 206010003805 Autism Diseases 0.000 claims 3
- 208000020706 Autistic disease Diseases 0.000 claims 3
- 208000032841 Bulimia Diseases 0.000 claims 3
- 206010006550 Bulimia nervosa Diseases 0.000 claims 3
- 206010008190 Cerebrovascular accident Diseases 0.000 claims 3
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 3
- 208000002193 Pain Diseases 0.000 claims 3
- 208000006011 Stroke Diseases 0.000 claims 3
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 206010013663 drug dependence Diseases 0.000 claims 3
- 230000000302 ischemic effect Effects 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 206010027599 migraine Diseases 0.000 claims 3
- 125000004043 oxo group Chemical group O=* 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 201000000980 schizophrenia Diseases 0.000 claims 3
- 208000011117 substance-related disease Diseases 0.000 claims 3
- YNYPRFFMZYCNAT-KGLIPLIRSA-N (4ar,9br)-4a,9b-dimethyl-2,3,4,5-tetrahydro-1h-indeno[1,2-b]pyridine Chemical compound C1C2=CC=CC=C2[C@@]2(C)[C@]1(C)CCCN2 YNYPRFFMZYCNAT-KGLIPLIRSA-N 0.000 claims 2
- VFLQTKJWHJXNHU-UONOGXRCSA-N (4ar,9br)-4a-ethyl-1,2,3,4,5,9b-hexahydroindeno[1,2-b]pyridine Chemical compound C1C2=CC=CC=C2[C@H]2[C@]1(CC)CCCN2 VFLQTKJWHJXNHU-UONOGXRCSA-N 0.000 claims 2
- JALVGPFKISCTCY-QWHCGFSZSA-N (4ar,9br)-4a-methyl-1,2,3,4,5,9b-hexahydroindeno[1,2-b]pyridine Chemical compound C1C2=CC=CC=C2[C@H]2[C@]1(C)CCCN2 JALVGPFKISCTCY-QWHCGFSZSA-N 0.000 claims 2
- YNYPRFFMZYCNAT-UONOGXRCSA-N (4as,9bs)-4a,9b-dimethyl-2,3,4,5-tetrahydro-1h-indeno[1,2-b]pyridine Chemical compound C1C2=CC=CC=C2[C@]2(C)[C@@]1(C)CCCN2 YNYPRFFMZYCNAT-UONOGXRCSA-N 0.000 claims 2
- VFLQTKJWHJXNHU-KGLIPLIRSA-N (4as,9bs)-4a-ethyl-1,2,3,4,5,9b-hexahydroindeno[1,2-b]pyridine Chemical compound C1C2=CC=CC=C2[C@@H]2[C@@]1(CC)CCCN2 VFLQTKJWHJXNHU-KGLIPLIRSA-N 0.000 claims 2
- JALVGPFKISCTCY-OLZOCXBDSA-N (4as,9bs)-4a-methyl-1,2,3,4,5,9b-hexahydroindeno[1,2-b]pyridine Chemical compound C1C2=CC=CC=C2[C@@H]2[C@@]1(C)CCCN2 JALVGPFKISCTCY-OLZOCXBDSA-N 0.000 claims 2
- YNYPRFFMZYCNAT-UHFFFAOYSA-N 4a,9b-dimethyl-2,3,4,5-tetrahydro-1h-indeno[1,2-b]pyridine Chemical compound C1C2=CC=CC=C2C2(C)C1(C)CCCN2 YNYPRFFMZYCNAT-UHFFFAOYSA-N 0.000 claims 2
- VFLQTKJWHJXNHU-UHFFFAOYSA-N 4a-ethyl-1,2,3,4,5,9b-hexahydroindeno[1,2-b]pyridine Chemical compound C1C2=CC=CC=C2C2C1(CC)CCCN2 VFLQTKJWHJXNHU-UHFFFAOYSA-N 0.000 claims 2
- JALVGPFKISCTCY-UHFFFAOYSA-N 4a-methyl-1,2,3,4,5,9b-hexahydroindeno[1,2-b]pyridine Chemical compound C1C2=CC=CC=C2C2C1(C)CCCN2 JALVGPFKISCTCY-UHFFFAOYSA-N 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- OCAMVVAPHMZSIV-UHFFFAOYSA-N (4a-ethyl-1,2,3,4,5,9b-hexahydroindeno[1,2-b]pyridin-8-yl)methanol Chemical compound C1C2=CC=C(CO)C=C2C2C1(CC)CCCN2 OCAMVVAPHMZSIV-UHFFFAOYSA-N 0.000 claims 1
- UUQCPNUYUOHBNL-UHFFFAOYSA-N 1,4a-dimethyl-3,4,5,9b-tetrahydro-2h-indeno[1,2-b]pyridine Chemical compound C1=CC=C2C3N(C)CCCC3(C)CC2=C1 UUQCPNUYUOHBNL-UHFFFAOYSA-N 0.000 claims 1
- IRDNVGBAIUXWDO-UHFFFAOYSA-N 1-methyl-4a-phenyl-3,4,5,9b-tetrahydro-2h-indeno[1,2-b]pyridine Chemical compound C1C2=CC=CC=C2C2N(C)CCCC21C1=CC=CC=C1 IRDNVGBAIUXWDO-UHFFFAOYSA-N 0.000 claims 1
- RAUPUJDISQBSQC-UHFFFAOYSA-N 2-(1,2,3,4,5,9b-hexahydroindeno[1,2-b]pyridin-4a-yl)-n,n-dimethylethanamine Chemical compound C1C2=CC=CC=C2C2C1(CCN(C)C)CCCN2 RAUPUJDISQBSQC-UHFFFAOYSA-N 0.000 claims 1
- UNHXACQXCQTOAC-UHFFFAOYSA-N 4a,7-dimethyl-1,2,3,4,5,8b-hexahydrothieno[1,2]cyclopenta[4,5-b]pyridine Chemical compound C12NCCCC2(C)CC2=C1C=C(C)S2 UNHXACQXCQTOAC-UHFFFAOYSA-N 0.000 claims 1
- UEIDNEPOTSHZAN-UHFFFAOYSA-N 4a-(ethoxymethyl)-1,2,3,4,5,9b-hexahydroindeno[1,2-b]pyridine Chemical compound C1C2=CC=CC=C2C2C1(COCC)CCCN2 UEIDNEPOTSHZAN-UHFFFAOYSA-N 0.000 claims 1
- BIKNHXYFFRUSBQ-UHFFFAOYSA-N 4a-(methoxymethyl)-9b-methyl-2,3,4,5-tetrahydro-1h-indeno[1,2-b]pyridine Chemical compound C1C2=CC=CC=C2C2(C)C1(COC)CCCN2 BIKNHXYFFRUSBQ-UHFFFAOYSA-N 0.000 claims 1
- FVLXPYVYRMTNBO-UHFFFAOYSA-N 4a-methyl-2,3,4,9b-tetrahydro-1h-[1]benzothiolo[3,2-b]pyridine Chemical compound C12=CC=CC=C2SC2(C)C1NCCC2 FVLXPYVYRMTNBO-UHFFFAOYSA-N 0.000 claims 1
- PWTWGKXZOKTOBZ-UHFFFAOYSA-N 4a-propan-2-yl-1,2,3,4,5,9b-hexahydroindeno[1,2-b]pyridine Chemical compound C1C2=CC=CC=C2C2C1(C(C)C)CCCN2 PWTWGKXZOKTOBZ-UHFFFAOYSA-N 0.000 claims 1
- KRLWKINTSFHJEU-UHFFFAOYSA-N 5a-methyl-2,3,4,5,6,10b-hexahydro-1h-indeno[1,2-b]azepine Chemical compound N1CCCCC2(C)C1C1=CC=CC=C1C2 KRLWKINTSFHJEU-UHFFFAOYSA-N 0.000 claims 1
- HNANUPYUGSFCDJ-UHFFFAOYSA-N 8-methoxy-1,4a-dimethyl-3,4,5,9b-tetrahydro-2h-indeno[1,2-b]pyridine Chemical compound C1CCN(C)C2C3=CC(OC)=CC=C3CC21C HNANUPYUGSFCDJ-UHFFFAOYSA-N 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/32—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems containing carbocyclic rings other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/78—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/06—Peri-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Indole Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Claims (15)
1. Spoj, naznačen time, da ima formulu (I) ili njegova farmaceutski prihvatljiva sol:
[image]
(gdje,
Prsten A predstavlja benzen-prsten ili tiofen-prsten,
R1 predstavlja C1-6 alkil koji može biti supstituiran s jednom ili više skupina odabranih iz skupine koju čine -OH,-O-C1-6alkil, amino koji može biti supstituiran s jednim ili dva C1-6alkila, i okso; -O-C1-6alkil; halogen; cijano; ili ciklički amino,
n predstavlja cijeli broj od 0 do 4 u slučaju gdje Prsten A predstavlja benzen-prsten, dok predstavlja cijeli broj od 0 do 2 u slučaju gdje Prsten A predstavlja tiofen-prsten,
R2 predstavlja -H ili C1-6 alkil,
R3 predstavlja C1-6 alkil koji može biti supstituiran sa sljedećima: fenil, cikloalkil ili -H,
R4 predstavlja C1-6 alkil koji može biti supstituiran s jednom ili više skupina odabranima iz skupine koju čine -OH, -O-C1-6alkil, amino koji može biti supstituiran s jednim ili dva
C1-6alkila, okso i ciklički amin; cikloalkil; aril; ili -OH,
X1 predstavlja -CH2-, -O-, -S- ili -CH(R0)-,
X2 predstavlja -C(RA)(RB)- ili -O-,
X3 predstavlja -C(RC)(RD)-,
m predstavlja cijeli broj od 1 do 3,
R0 predstavlja -H, ili je R0 u kombinaciji s R4 kada predstavljaju C3-5 alkilen, te su
RA, RB, RC i RD međusobno isti ili različiti, a predstavljaju -H ili C1-6 alkil,
gdje, u slučaju da m predstavlja 2 ili 3, svaki od RC i RD može biti isti ili različit,
uz uvjet da su izuzeti slijedeći spojevi:
1-metil-4a-fenil-2,3,4,4a,5,9b-heksahidro-1H-indeno[1,2-b]piridin,
4a-fenil-2,3,4,4a,5,9b-heksahidro-1H-indeno[1,2-b]piridin, i
2-(1,2,3,4,5,9b-heksahidro-4aH-indeno[1,2-b]piridin-4a-il)-N,N-dimetiletanamin.)
2. Spoj ili njegova farmaceutski prihvatljiva sol prema zahtjevu 1, naznačen time, da Prsten A je benzen-prsten.
3. Spoj ili njegova farmaceutski prihvatljiva sol prema zahtjevu 1, naznačen time, da Prsten A je tiofen-prsten.
4. Spoj ili njegova farmaceutski prihvatljiva sol prema jednom od zahtjeva 2 ili 3, naznačen time, da X1 je -CH2-, X2je -CH2-, X3 je -CH2-, i m je 2.
5. Spoj ili njegova farmaceutski prihvatljiva sol prema zahtjevu 4, naznačen time, da R4 je C1-6 alkil koji može biti supstituiran s jednom ili više skupina odabranih iz skupine koju čine -OH, -O-C1-6 alkil, amino koji može biti supstituiran s jednim ili dva C1-6 alkila, okso, te ciklički amin.
6. Spoj ili njegova farmaceutski prihvatljiva sol prema zahtjevu 5, naznačen time, da R4 je metil, etil, izopropil, metoksimetil ili etoksimetil.
7. Spoj ili njegova farmaceutski prihvatljiva sol prema zahtjevu 6, naznačen time, da R3 je -H, metil ili etil.
8. Spoj ili njegova farmaceutski prihvatljiva sol prema zahtjevu 7, naznačen time, da R2 je -H ili metil.
9. Spoj ili njegova farmaceutski prihvatljiva sol prema zahtjevu 8, naznačen time, da n je 0.
10. Spoj ili njegova farmaceutski prihvatljiva sol prema zahtjevu 1, naznačen time, da je
(4aRS,9bRS)-4a-metil-2,3,4,4a, 5,9b-heksahidro-1H-indeno[1,2-b]piridin,
(4aRS,9bRS)-1,4a-dimetil-2,3,4,4a,5,9b-heksahidro-1H-indeno[1,2-b]piridin,
(4aRS,9bRS)-4a-etil-2,3,4,4a,5,9b-heksahidro-1H-indeno[1,2-b]piridin,
(4aR,9bR)-4a-metil-2,3,4, 4a,5,9b-heksahidro-1H-indeno[1,2-b]piridin,
(4aS,9bS)-4a-metil-2,3,4,4a,5,9b-heksahidro-1H-indeno[1,2-b]piridin,
(4aRS,9bSR)-4a-izopropil-2,3,4,4a,5,9b-heksahidro-1H-indeno[1,2-b]piridin,
(4aR,9bR)-4a-etil-2,3,4,4a,5,9b-heksahidro-1H-indeno[1,2-b]piridin,
(4aS,9bS)-4a-etil-2,3,4,4a,5,9b-heksahidro-1H-indeno[1,2-b]piridin,
(4aRS,9bRS)-8-metoksi-1,4a-dimetil-2,3,4,4a,5,9b-heksahidro-1H-indeno[1,2-b]piridin,
(4aRS,9bRS)-4a,9b-dimetil-2,3,4,4a,5,9b-heksahidro-1H-indeno[1,2-b]piridin,
(4aRS,9bRS)4a-(etoksimetil)-2,3,4,4a,5,9b-heksahidro-1H-indeno[1,2-b]piridin,
(3bRS,7aRS)-2,7a-dimetil-4,5,6,7,7a,8-heksahidro-3bH-tieno[2’,3’:4,5]ciklopenta[1,2-b]piridin,
(4aRS,9bRS)-4a-(metoksimetil)-9b-metil-2,3,4,4a,5,9b-heksahidro-1H-indeno[1,2-b]piridin,
(5aRS,10bSR)-5a-metil-1,2,3,4,5,5a,6,10b-oktahidroindeno[1,2-b]azepin,
[(4aRS,9bRS)-4a-etil-2,3,4,4a,5,9b-heksahidro-1H-indeno[1,2-b]piridin-8-il]metanol,
(4aRS,9bRS)-4a-metil-1,2,3,4,4a,9b-heksahido[1]benzotieno[3,2-b]piridin,
(4aR,9bR)-4a,9b-dimetil-2,3,4,4a,5,9b-heksahidro-1H-indeno[1,2-b]piridin, ili
(4aS,9bS)-4a,9b-dimetil-2,3,4,4a,5,9b-heksahidro-1H-indeno[1,2-b]piridin,
ili njegova farmceutski prihvatljiva sol.
11. Spoj ili njegova farmaceutski prihvatljiva sol prema zahtjevu 1, naznačen time, da je
(4aRS,9bRS)-4a-metil-2,3,4,4a,5,9b-heksahidro-1H-indeno[1,2-b]piridin,
(4aR,9bR)-4a-metil-2,3,4,4a,5,9b-heksahidro-1H-indeno[1,2-b]piridin,
(4aS,9bS)-4a-metil-2,3,4,4a,5,9b-heksahidro-1H-indeno[1,2-b]piridin,
(4aRS,9bRS)-4a-etil-2,3,4,4a,5,9b-heksahidro-1H-indeno[1,2-b]piridin,
(4aR,9bR)-4a-etil-2,3,4,4a,5,9b-heksahidro-1H-indeno[1,2-b]piridin,
(4aS,9bS)-4a-etil-2,3,4,4a,5,9b-heksahidro-1H-indeno[1,2-b]piridin,
(4aRS,9bRS)4a,9b-dimetil-2,3,4,4a,5,9b-heksahidro-1H-indeno[1,2-b]piridin,
(4aR,9bR)-4a,9b-dimetil-2,3,4,4a,5,9b-heksahidro-1H-indeno[1,2-b]piridin, ili
(4aS,9bS)-4a,9b-dimetil-2,3,4,4a,5,9b-heksahidro-1H-indeno[1,2-b]piridin,
ili njegova farmaceutski prihvatljiva sol.
12. Farmaceutski sastav, naznačen time, da obuhvaća spoj ili njegovu farmaceutski prihvatljivu sol prema zahtjevu 1, te farmaceutski prihvatljivo pomoćno sredstvo.
13. Farmaceutski sastav, naznačen time, da je za liječenje Alzheimer-ove bolesti, cerebrovaskularne demencije, Parkinson-ove bolesti, ishemijske apopleksije, bolova, neukrotive depresije, poremećaja hiperaktivnosti s nedostatkom pažnje, migrena, shizofrenije, poremećaja opće anksioznosti, opsesivno-kompulzivnog poremećaja, autizma, bulimije ili ovisnosti o drogama, te da obuhvaća spoj ili njegovu farmaceutski prihvatljivu sol prema zahtjevu 1, ili 4a-fenil-2,3,4,4a,5,9b-heksahidro-1H-indeno[1,2-b]piridin ili njegovu farmaceutski prihvatljivu sol kao i farmaceutski prihvatljivo pomoćno sredstvo.
14. Uporaba spoja ili njegove farmaceutski prihvatljive soli prema zahtjevu 1, ili 4a-fenil-2,3,4,4a,5,9b-heksahidro-1H-indeno[1,2-b]piridina ili njegove farmaceutski prihvatljive soli, naznačena time, da je za proizvodnju farmaceutskog sastava za liječenje Alzheimer-ove bolesti, cerebrovaskularne demencije, Parkinson-ove bolesti, ishemijske apopleksije, bolova, neukrotive depresije, poremećaja hiperaktivnosti s nedostatkom pažnje, migrena, shizofrenije, poremećaja opće anksioznosti, opsesivno-kompulzivnog poremećaja, autizma, bulimije ili ovisnosti o drogama.
15. Uporaba prema zahtjevu 14, naznačena time, da farmaceutski sastav za liječenje Alzheimer-ove bolesti, cerebrovaskularne demencije, Parkinson-ove bolesti, ishemijske apopleksije, bolova, neukrotive depresije, poremećaja hiperaktivnosti s nedostatkom pažnje, migrena, shizofrenije, poremećaja opće anksioznosti, opsesivno-kompulzivnog poremećaja, autizma, bulimije ili ovisnosti o drogama, je farmaceutski sastav za liječenje Alzheimer-ove bolesti, cerebrovaskularne demencije, Parkinson-ove bolesti, neukrotive depresije, poremećaja hiperaktivnosti s nedostatkom pažnje ili migrena.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007307753 | 2007-11-28 | ||
PCT/JP2008/071370 WO2009069610A1 (ja) | 2007-11-28 | 2008-11-26 | 縮合インダン化合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20120944T1 true HRP20120944T1 (hr) | 2012-12-31 |
Family
ID=40678506
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20120944AT HRP20120944T1 (hr) | 2007-11-28 | 2012-11-20 | Kondenzirani spoj indana |
Country Status (21)
Country | Link |
---|---|
US (1) | US8211907B2 (hr) |
EP (1) | EP2221296B1 (hr) |
JP (1) | JP5251885B2 (hr) |
KR (1) | KR101497747B1 (hr) |
CN (1) | CN101878201B (hr) |
AU (1) | AU2008330653B2 (hr) |
BR (1) | BRPI0819795B8 (hr) |
CA (1) | CA2706171C (hr) |
CY (1) | CY1113634T1 (hr) |
DK (1) | DK2221296T3 (hr) |
ES (1) | ES2391235T3 (hr) |
HR (1) | HRP20120944T1 (hr) |
IL (1) | IL205551A (hr) |
MX (1) | MX2010005928A (hr) |
PL (1) | PL2221296T3 (hr) |
PT (1) | PT2221296E (hr) |
RU (1) | RU2451671C2 (hr) |
SI (1) | SI2221296T1 (hr) |
TW (1) | TWI422578B (hr) |
WO (1) | WO2009069610A1 (hr) |
ZA (1) | ZA201003112B (hr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2998892B1 (fr) | 2012-12-04 | 2015-01-02 | Pf Medicament | Derives d'aminocyclobutane, leur procede de preparation et leur utilisation a titre de medicaments |
CN113234036B (zh) * | 2021-05-12 | 2023-07-14 | 斯莱普泰(上海)生物医药科技有限公司 | Nmda受体拮抗剂及其用途 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK12293D0 (da) * | 1993-02-02 | 1993-02-02 | Novo Nordisk As | Heterocykliske forbindelser og deres fremstilling og anvendelse |
US5574060A (en) * | 1993-08-12 | 1996-11-12 | The United States Of America As Represented By The Department Of Health And Human Services | Selective inhibitors of biogenic amine transporters |
US6472378B2 (en) | 1998-08-31 | 2002-10-29 | Pro-Neuron, Inc. | Compositions and methods for treatment of mitochondrial diseases |
TW200621677A (en) * | 2004-09-21 | 2006-07-01 | Astellas Pharma Inc | Cyclic amine derivative or salt thereof |
DE102005010000A1 (de) | 2005-03-04 | 2006-09-07 | Merck Patent Gmbh | Indane |
-
2008
- 2008-11-26 DK DK08853617.2T patent/DK2221296T3/da active
- 2008-11-26 KR KR1020107011747A patent/KR101497747B1/ko active IP Right Grant
- 2008-11-26 JP JP2009543802A patent/JP5251885B2/ja not_active Expired - Fee Related
- 2008-11-26 BR BRPI0819795A patent/BRPI0819795B8/pt active IP Right Grant
- 2008-11-26 ES ES08853617T patent/ES2391235T3/es active Active
- 2008-11-26 EP EP08853617A patent/EP2221296B1/en active Active
- 2008-11-26 CA CA2706171A patent/CA2706171C/en active Active
- 2008-11-26 US US12/741,307 patent/US8211907B2/en active Active
- 2008-11-26 PL PL08853617T patent/PL2221296T3/pl unknown
- 2008-11-26 SI SI200830759T patent/SI2221296T1/sl unknown
- 2008-11-26 MX MX2010005928A patent/MX2010005928A/es active IP Right Grant
- 2008-11-26 AU AU2008330653A patent/AU2008330653B2/en not_active Ceased
- 2008-11-26 CN CN2008801180038A patent/CN101878201B/zh active Active
- 2008-11-26 PT PT08853617T patent/PT2221296E/pt unknown
- 2008-11-26 RU RU2010126202/04A patent/RU2451671C2/ru active
- 2008-11-26 WO PCT/JP2008/071370 patent/WO2009069610A1/ja active Application Filing
- 2008-11-27 TW TW097145948A patent/TWI422578B/zh active
-
2010
- 2010-05-04 ZA ZA2010/03112A patent/ZA201003112B/en unknown
- 2010-05-05 IL IL205551A patent/IL205551A/en active IP Right Grant
-
2012
- 2012-11-19 CY CY20121101110T patent/CY1113634T1/el unknown
- 2012-11-20 HR HRP20120944AT patent/HRP20120944T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
EP2221296A1 (en) | 2010-08-25 |
SI2221296T1 (sl) | 2012-10-30 |
AU2008330653B2 (en) | 2012-08-16 |
EP2221296B1 (en) | 2012-09-05 |
ES2391235T3 (es) | 2012-11-22 |
KR101497747B1 (ko) | 2015-03-04 |
PT2221296E (pt) | 2012-11-23 |
JPWO2009069610A1 (ja) | 2011-04-14 |
BRPI0819795B8 (pt) | 2021-05-25 |
TW200936568A (en) | 2009-09-01 |
TWI422578B (zh) | 2014-01-11 |
RU2451671C2 (ru) | 2012-05-27 |
KR20100091995A (ko) | 2010-08-19 |
PL2221296T3 (pl) | 2013-01-31 |
US8211907B2 (en) | 2012-07-03 |
US20100267695A1 (en) | 2010-10-21 |
CA2706171A1 (en) | 2009-06-04 |
CN101878201A (zh) | 2010-11-03 |
WO2009069610A1 (ja) | 2009-06-04 |
CN101878201B (zh) | 2012-09-05 |
MX2010005928A (es) | 2010-06-15 |
BRPI0819795A2 (pt) | 2015-05-26 |
DK2221296T3 (da) | 2012-09-24 |
IL205551A0 (en) | 2010-12-30 |
CY1113634T1 (el) | 2016-06-22 |
RU2010126202A (ru) | 2012-01-10 |
JP5251885B2 (ja) | 2013-07-31 |
IL205551A (en) | 2015-05-31 |
BRPI0819795B1 (pt) | 2019-10-15 |
AU2008330653A1 (en) | 2009-06-04 |
EP2221296A4 (en) | 2011-04-27 |
ZA201003112B (en) | 2011-07-27 |
CA2706171C (en) | 2013-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20080051409A1 (en) | Indolizine Carboxamides and Aza and Diaza Derivatives Thereof | |
Mabire et al. | Synthesis, structure− activity relationship, and receptor pharmacology of a new series of quinoline derivatives acting as selective, noncompetitive mGlu1 antagonists | |
AU2007280428B2 (en) | Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine | |
AU2020201091A1 (en) | Methods of manufacturing benzoquinoline compounds | |
US20030060464A1 (en) | Therapeutic 1H-pyrido [ 4, 3-b ] indoles | |
US6514968B1 (en) | Aminoalkoxy carbazoles for the treatment of cns diseases | |
HRP20170153T1 (hr) | Novi derivati indolizina, postupak njihove priprave i farmaceutski pripravci koji ih sadrže za liječenje karcinoma | |
CN107849037A (zh) | 用于治疗和预防乙型肝炎病毒感染的新的三环4‑吡啶酮‑3‑甲酸衍生物 | |
AR040351A1 (es) | Derivados de quinuclidina-amida, composicion farmaceutica, procedimiento de preparacion del compuesto y su uso para fabricar medicamentos | |
RS53282B (en) | TIENO (2,3-B) PIRIDINDION AMPK ACTIVATORS AND THEIR THERAPEUTIC USES | |
AR096371A1 (es) | 2-fenilimidazo[1,2-a]pirimidinas | |
HRP20140717T1 (hr) | Derivati naftalen karboksamida kao inhibitori protein kinaze i histon deacetilaze, postupci njihove pripreme i njihove uporabe | |
HRP20151273T1 (hr) | Heterocikliäśki spojevi fenoksilmetila | |
NZ517900A (en) | Phenylpiperazines useful as serotonin reuptake inhibitors | |
AR051333A1 (es) | Derivados de benzodiaepina sustituida por halogeno | |
CN100372845C (zh) | 作为有效的α2-肾上腺素受体拮抗剂的多环化合物 | |
TW200817351A (en) | Aminoindan derivative or salt thereof | |
HRP20120876T1 (hr) | Brzo disocirajuä†i antagonisti dopamin 2 receptora | |
JP2021042255A (ja) | Creb結合タンパク質(cbp)の阻害 | |
HRP20090565T1 (hr) | Novi triciklički derivati, postupak njihove priprave i farmaceutski pripravci koji ih sadrže | |
HRP20120944T1 (hr) | Kondenzirani spoj indana | |
Barbay et al. | Synthesis and characterization of 5, 6, 7, 8-tetrahydroquinoline C5a receptor antagonists | |
ATE443707T1 (de) | Isoxazolin-indol-derivate mit verbesserter antipsychotischer und anxiolytischer aktivität | |
Zhu et al. | Aporphines: A privileged scaffold in CNS drug discovery | |
PT97286B (pt) | Processo para a preparacao de novos derivados do 3-aminocromano e de composicoes farmaceuticas que os contem |